The landscape of cancer treatment changed forever in 1998, when U.S. authorities approved the first genetically tailored precision cancer therapy. The drug, Herceptin, zeroes in on the activity of ...
Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...
If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results